Visx meeting with FDA to discuss Star PRK laser's high myopia, astigmatism capacities.
This article was originally published in The Gray Sheet
VISX STAR PRK LASER SOFTWARE WITH HIGH MYOPIA, ASTIGMATISM CAPABILITY was part of the Star photorefractive keratectomy laser system approved by FDA March 27 although the agency did not approve the two indications, Visx maintains. Visx' statement responds to Summit allegations, spelled out in a June 24 letter to FDA, that by providing software capable of treating high myopia and astigmatism, Visx is "intentionally distributing unapproved devices."
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.